GT201300040A - Quelatos de oligonucleótidos - Google Patents
Quelatos de oligonucleótidosInfo
- Publication number
- GT201300040A GT201300040A GT201300040A GT201300040A GT201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A
- Authority
- GT
- Guatemala
- Prior art keywords
- oligonucleotide
- divalent
- chelation
- cations
- cheats
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 7
- 150000001768 cations Chemical class 0.000 abstract 2
- 230000009920 chelation Effects 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000010100 anticoagulation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000001457 metallic cations Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
Abstract
LA PRESENTE DIVULGACIÓN DESCRIBE LA QUELACIÓN AMPLIAMENTE ACTIVA DE DIVERSOS CATIONES METÁLICOS DIVALENTES 2+ MEDIANTE CUALQUIER OLIGONUCLEÓTIDO (ON), SIN IMPORTAR EL TAMAÑO O LA MODIFICACIÓN. ESTE EFECTO DE QUELACIÓN ES ESPECÍFICO PARA CATIONES QUE SON DIVALENTES (O DE VALENCIA MAYOR) Y DA COMO RESULTADO LA FORMACIÓN DE QUELATOS DE OLIGONUCLEÓTIDOS QUE NO SE COMPORTAN COMO SALES.SE DESCRIBE EN LA PRESENTE UNA COMPOSICIÓN NOVEDOSA DE UN QUELATO DE ON PREPARADO USANDO CUALQUIER ON Y UN CATIÓN METÁLICO DIVALENTE Y MÉTODOS PARA SUPRIMIR LA ANTICOAGULACIÓN Y/O LAS REACCIONES EN EL SITIO DE INYECCIÓN SUBCUTÁNEA Y/O TOLERABILIDAD MEJORADA CON OLIGONUCLEÓTIDOS MEDIANTE EL USO DE QUELATOS DE ON DURANTE LA ADMINISTRACIÓN DE OLIGONUCLEÓTIDOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37525710P | 2010-08-20 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201300040A true GT201300040A (es) | 2014-09-02 |
Family
ID=45594559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201300040A GT201300040A (es) | 2010-08-20 | 2013-02-14 | Quelatos de oligonucleótidos |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8513211B2 (es) |
| EP (1) | EP2605794B1 (es) |
| JP (1) | JP5775581B2 (es) |
| KR (3) | KR101606495B1 (es) |
| CN (2) | CN103052405B (es) |
| AU (1) | AU2011291401B2 (es) |
| BR (1) | BR112013003875B1 (es) |
| CA (2) | CA2855690C (es) |
| CL (1) | CL2013000445A1 (es) |
| CO (1) | CO6670525A2 (es) |
| CR (1) | CR20130069A (es) |
| CU (1) | CU20130022A7 (es) |
| CY (1) | CY1118207T1 (es) |
| DK (1) | DK2605794T3 (es) |
| DO (1) | DOP2013000041A (es) |
| EA (1) | EA026660B1 (es) |
| EC (1) | ECSP13012449A (es) |
| ES (1) | ES2598556T3 (es) |
| GT (1) | GT201300040A (es) |
| HR (1) | HRP20161333T1 (es) |
| HU (1) | HUE029521T2 (es) |
| IL (1) | IL224237A (es) |
| LT (1) | LT2605794T (es) |
| MX (1) | MX340294B (es) |
| MY (1) | MY160961A (es) |
| NZ (1) | NZ606364A (es) |
| PH (1) | PH12013500192B1 (es) |
| PL (1) | PL2605794T3 (es) |
| PT (1) | PT2605794T (es) |
| RS (1) | RS55245B1 (es) |
| SG (1) | SG187165A1 (es) |
| SI (1) | SI2605794T1 (es) |
| SM (1) | SMT201600370B (es) |
| WO (1) | WO2012021985A1 (es) |
| ZA (1) | ZA201300497B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2660523C (en) | 2006-08-11 | 2019-03-19 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| DK2158316T3 (en) | 2007-05-11 | 2015-07-20 | Adynxx Inc | Gene expression and pain |
| PL2203173T3 (pl) | 2007-10-26 | 2016-06-30 | Academisch Ziekenhuis Leiden | Środki i sposoby przeciwdziałania zaburzeniom mięśni |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
| RS56319B1 (sr) | 2012-04-23 | 2017-12-29 | Biomarin Tech Bv | Oligonukleotidi koji moduliraju rnk sa poboljšanim karakteristikama za lečenje neuromišićnih poremećaja |
| RU2668136C2 (ru) * | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| HRP20210840T1 (hr) * | 2012-05-18 | 2021-08-06 | Replicor Inc. | Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci |
| AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| CA2877644A1 (en) * | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| BR112015003985A2 (pt) * | 2012-08-30 | 2017-08-08 | Replicor Inc | métodos para tratamento de infecções de hepatite b e hepatite d |
| HUE064449T2 (hu) | 2014-07-10 | 2024-03-28 | Replicor Inc | Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra |
| ES2750689T3 (es) | 2014-08-15 | 2020-03-26 | Adynxx Inc | Señuelos oligonucleotídicos para el tratamiento del dolor |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| JP2018513127A (ja) * | 2015-04-23 | 2018-05-24 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | 多価カチオン塩組成物を用いたポリヌクレオチド調製方法 |
| AU2019376079A1 (en) * | 2018-11-08 | 2021-05-27 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20230250125A1 (en) | 2020-04-01 | 2023-08-10 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| WO2022109129A1 (en) * | 2020-11-20 | 2022-05-27 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| WO2023281434A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Pharmaceuticals, Inc. | Use of oligonucleotides for individuals with renal impairment |
| WO2024255846A1 (en) * | 2023-06-16 | 2024-12-19 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2300938A1 (en) * | 1997-08-20 | 1999-02-25 | Somagenics, Inc. | Antisense and antigene therapeutics with improved binding properties and methods for their use |
| JP3667047B2 (ja) * | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| JP4836366B2 (ja) * | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
| JP4783149B2 (ja) * | 2003-09-02 | 2011-09-28 | 独立行政法人科学技術振興機構 | 金属錯体型核酸 |
| WO2005026188A1 (ja) * | 2003-09-08 | 2005-03-24 | Japan Science And Technology Agency | 金属錯体型核酸 |
| JP2009500020A (ja) * | 2005-07-01 | 2009-01-08 | バイオヴェリス コーポレイション | 核酸を検出、増幅および／また単離するための組成物および方法 |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
-
2011
- 2011-08-18 KR KR1020137007008A patent/KR101606495B1/ko not_active Expired - Fee Related
- 2011-08-18 EA EA201300259A patent/EA026660B1/ru unknown
- 2011-08-18 CN CN201180035946.6A patent/CN103052405B/zh active Active
- 2011-08-18 MX MX2013001668A patent/MX340294B/es active IP Right Grant
- 2011-08-18 EP EP11817618.9A patent/EP2605794B1/en active Active
- 2011-08-18 CA CA2855690A patent/CA2855690C/en active Active
- 2011-08-18 US US13/212,306 patent/US8513211B2/en active Active
- 2011-08-18 MY MYPI2013000544A patent/MY160961A/en unknown
- 2011-08-18 PT PT118176189T patent/PT2605794T/pt unknown
- 2011-08-18 BR BR112013003875-6A patent/BR112013003875B1/pt not_active IP Right Cessation
- 2011-08-18 CA CA2806616A patent/CA2806616C/en active Active
- 2011-08-18 NZ NZ606364A patent/NZ606364A/en unknown
- 2011-08-18 LT LTEP11817618.9T patent/LT2605794T/lt unknown
- 2011-08-18 PH PH1/2013/500192A patent/PH12013500192B1/en unknown
- 2011-08-18 KR KR20157007582A patent/KR20150039873A/ko not_active Withdrawn
- 2011-08-18 KR KR1020157017340A patent/KR20150082685A/ko not_active Withdrawn
- 2011-08-18 PL PL11817618T patent/PL2605794T3/pl unknown
- 2011-08-18 JP JP2013524318A patent/JP5775581B2/ja active Active
- 2011-08-18 DK DK11817618.9T patent/DK2605794T3/en active
- 2011-08-18 ES ES11817618.9T patent/ES2598556T3/es active Active
- 2011-08-18 RS RS20160869A patent/RS55245B1/sr unknown
- 2011-08-18 HU HUE11817618A patent/HUE029521T2/en unknown
- 2011-08-18 CN CN201410046103.1A patent/CN103768086B/zh active Active
- 2011-08-18 AU AU2011291401A patent/AU2011291401B2/en active Active
- 2011-08-18 HR HRP20161333TT patent/HRP20161333T1/hr unknown
- 2011-08-18 SI SI201130985A patent/SI2605794T1/sl unknown
- 2011-08-18 WO PCT/CA2011/000956 patent/WO2012021985A1/en not_active Ceased
- 2011-08-18 SG SG2013004957A patent/SG187165A1/en unknown
-
2013
- 2013-01-15 IL IL224237A patent/IL224237A/en active IP Right Grant
- 2013-01-18 ZA ZA2013/00497A patent/ZA201300497B/en unknown
- 2013-02-11 CO CO13027675A patent/CO6670525A2/es unknown
- 2013-02-13 CL CL2013000445A patent/CL2013000445A1/es unknown
- 2013-02-14 DO DO2013000041A patent/DOP2013000041A/es unknown
- 2013-02-14 GT GT201300040A patent/GT201300040A/es unknown
- 2013-02-19 EC ECSP13012449 patent/ECSP13012449A/es unknown
- 2013-02-19 CR CR20130069A patent/CR20130069A/es unknown
- 2013-02-20 CU CU2013000022A patent/CU20130022A7/es unknown
- 2013-05-30 US US13/905,318 patent/US8716259B2/en active Active
-
2016
- 2016-10-13 SM SM201600370T patent/SMT201600370B/it unknown
- 2016-10-17 CY CY20161101037T patent/CY1118207T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300040A (es) | Quelatos de oligonucleótidos | |
| AR091604A1 (es) | Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto | |
| MX2015017532A (es) | Métodos para modular la actividad del regulador de transmembrana de fibrosis quística. | |
| MX373763B (es) | Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica. | |
| EP4335507A3 (en) | Combination therapy | |
| PE20160190A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| EA201591767A8 (ru) | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии | |
| CU20120161A7 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas | |
| BR112017008198A2 (pt) | pró-fármacos de carbidopa e l-dopa e métodos de uso | |
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| PH12013500449A1 (en) | Treatment of diseases | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| ECSP10010494A (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
| MX386613B (es) | El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| UY31849A (es) | Nuevos compuestos como inhibidores de pde4 | |
| CR20140367A (es) | Inhibidores de iap | |
| MX380847B (es) | Composiciones para el cuidado bucal y métodos de uso. | |
| WO2014205127A3 (en) | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets | |
| MX374671B (es) | Complejo de zinc fosfato para el cuidado bucal. | |
| MX376016B (es) | Composiciones para el cuidado personal con activo de fosfato de zinc. | |
| IN2015DN02233A (es) | ||
| BR112012028409A2 (pt) | método para produzir pleurodese em um sujeito mamífero e kit. |